Advertisement

GUROPA survey: genito-urinary radiation oncology prescription attitudes

  • Sergio Fersino
  • Stefano Arcangeli
  • Barbara Alicja Jereczek-Fossa
  • Rolando D’Angelillo
  • Filippi Bertoni
  • Giuseppe Roberto D’Agostino
  • Luca Triggiani
  • Renzo Corvò
  • Stefano Maria Magrini
  • Filippo Alongi
  • on the behalf of AIRO
RADIOTHERAPY

Abstract

Aims

To investigate the role of Radiation Oncology in the management of genito-urinary (GU) cancer excluding prostate and penile cancer.

Methods

The questionnaire was focused on the evaluation of the degree of involvement of radiation oncologists in the work-up of bladder, renal cell carcinoma and testicular cancer (TC).

Results

Eighty-eight radiation oncologists completed the survey. The majority (85.4%) of participating radiation oncologists were senior consultants (> 5 years of experience). Sixty-four (73.6%) carried out a multidisciplinary tumor board discussion of GU cases, while 23 (26.4%) did not. Seventy-five percent of responders reported that, every year, visited < 50 GU patients (pts), 18.1% visited 50–100 pts and 6.9% visited > 100 pts. Bladder cancer, curative radiotherapy (RT) as part of trimodality approach was claimed to be adopted in less than 10 cases per year. Regarding renal cell carcinoma (RCC) patients, primary tumor directed RT was adopted only in 8 cases (9.4%) in at least 10 pts per year. Palliative RT was more frequent in RCC (48.2%) in over than 10 pts per year. In case of TC, the prescription of RT was limited (< 10 patients per year) due to the low incidence of disease and recent shift to surveillance as a first option in stage I seminoma.

Conclusions

Our survey showed that radiation oncologists are rarely involved in the decision making strategy of GU cancer, despite many clinical trials support RT use. These patients probably deserve a more uniform approach based on updated, detailed and evidence-based recommendations.

Keywords

Genito-urinary Cancer Radiotherapy Italian survey 

Notes

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

This article does not contain any studies with human participants performed by any of the authors.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30CrossRefPubMedGoogle Scholar
  2. 2.
    Antoni S, Ferlay J, Soerjomataram I et al (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71(1):96–108CrossRefPubMedGoogle Scholar
  3. 3.
    Epstein JI, Amin MB, Reuter VE et al (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 22:1435–1448CrossRefPubMedGoogle Scholar
  4. 4.
  5. 5.
    Bellmunt J, Orsola A, Leow JJ et al (2014) Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii40-8CrossRefPubMedGoogle Scholar
  6. 6.
    Caffo O, Veccia A, Fellin G et al (2013) Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature. Crit Rev Oncol Hematol 86(2):176–190CrossRefPubMedGoogle Scholar
  7. 7.
    Linee Guida AIRO-AIRB (2018) Neoplasie della Vescica. Tumori J (accepted)Google Scholar
  8. 8.
    Walker M, Doiron RC, French SD et al (2017) Bladder-sparing radiotherapy for muscle-invasive bladder cancer: a qualitative study to identify barriers and enablers. Clin Oncol 2017(29):818–826CrossRefGoogle Scholar
  9. 9.
    Jereczek-Fossa BA, Colombo R, Magnani T et al (2015) Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. Tumori 101(2):174–178CrossRefPubMedGoogle Scholar
  10. 10.
    Alongi F, Arcangeli S, Triggiani L et al (2017) Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease. Crit Rev Oncol Hematol 117:48–56CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159CrossRefPubMedGoogle Scholar
  12. 12.
    Kulkarni GS, Hermanns T, Wei Y et al (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35(20):2299–2305CrossRefPubMedGoogle Scholar
  13. 13.
    Scarberry K K, Ponsky L, Cherullo E et al (2018) Evaluating the impact of the genitourinary multidisciplinary tumour board: should every cancer patient be discussed as standard of care? Can Urol Assoc J.  https://doi.org/10.5489/cuaj.5150 PubMedGoogle Scholar
  14. 14.
    Valdagni R, Van Poppel H, Aitchison M et al (2015) Prostate cancer unit initiative in Europe: a position paper by the European School of Oncology. Crit Rev Oncol Hematol 95(2):133–143CrossRefPubMedGoogle Scholar
  15. 15.
    Chang SS, Bochner Bh, Chou R et al (2017) Treatment of nonmetastatic muscle-invasive bladder cancer: American Urological Association/American Society of Clinical Oncology/American Society for radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract 13(9):621–625CrossRefPubMedGoogle Scholar
  16. 16.
    Baumann BC, Bosch WR, Bahl A et al (2016) Development and validation of consensus contouring guidelines for adjuvant radiation therapy for bladder cancer after radical cystectomy. Int J Radiat Oncol Biol Phys 96(1):78–86CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fonteyne V, Dirix P, Junius S et al (2017) Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial. BMC Cancer 17(1):308CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Solanki AA, Martin B, Korpics M et al (2017) Adjuvant radiotherapy use by US radiation oncologists after radical cystectomy for muscle-invasive bladder cancer. Clin Oncol (R Coll Radiol) 29(7):429–435CrossRefGoogle Scholar
  19. 19.
    Gilson B, Lederman G, Qian G et al (2006) Hypo-fractionated stereotactic extra-cranial radiosurgery (HFSR) for primary and metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 2249(66):S349CrossRefGoogle Scholar
  20. 20.
    Siva S, Jackson P, Kron T et al (2016) Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose–response relationship. Radiother Oncol 118(3):540–546CrossRefPubMedGoogle Scholar
  21. 21.
    Jereczek-Fossa BA, Bortolato B, Gerardi MA et al (in press) Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of lombardy (airo-lombardy), Italy. Radiol Med (accepted)Google Scholar
  22. 22.
    Huber J, Ihrig A, Winkler E et al (2015) Interdisciplinary counseling service for renal malignancies: a patient-centered approach to raise guideline adherence. Urol Oncol 33(1):23.e1–23.e7CrossRefGoogle Scholar
  23. 23.
    Gayed BA, Youssef R, Darwish O et al (2016) Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned. BMC Urol 16(1):43CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/cns.pdfGoogle Scholar
  25. 25.
    Petrelli F, Coinu A, Cabiddu M et al (2015) Surveillance of adjuvant treatment with chemotherapy or radiotherapy in Stage 1 seminoma: a systematic review and metaanalysis of 13 studies. Clin Genitourin Cancer 13:193–198CrossRefPubMedGoogle Scholar
  26. 26.
    Ke KM, Blazeby JM, Strong S et al (2013) Are multidisciplinary teams in secondary care cost-effective? A systematic review of the literature. Cost Eff Resour Alloc 11(1):7.  https://doi.org/10.1186/1478-7547-11-7 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Italian Society of Medical Radiology 2018

Authors and Affiliations

  • Sergio Fersino
    • 1
  • Stefano Arcangeli
    • 2
  • Barbara Alicja Jereczek-Fossa
    • 3
  • Rolando D’Angelillo
    • 4
  • Filippi Bertoni
    • 5
  • Giuseppe Roberto D’Agostino
    • 6
  • Luca Triggiani
    • 7
  • Renzo Corvò
    • 8
  • Stefano Maria Magrini
    • 7
  • Filippo Alongi
    • 1
    • 9
  • on the behalf of AIRO
  1. 1.Radiation Oncology DepartmentOspedale Sacro-Cuore Don CalabriaNegrarItaly
  2. 2.Radiation Oncology DepartmentAzienda Ospedaliera San Camillo-ForlaniniRomeItaly
  3. 3.European Institute of OncologyUniversity of MilanMilanItaly
  4. 4.Department of Radiation OncologyCampus Biomedico UniversityRomeItaly
  5. 5.Genito-Urinary Group of AIRO - Italian Association for Radiation OncologyRomeItaly
  6. 6.Radiosurgery and Radiotherapy DepartmentIstituto Clinico Humanitas Cancer Center and Research HospitalRozzano, MilanItaly
  7. 7.Department of Radiation OncologyUniversity and Spedali Civili HospitalBresciaItaly
  8. 8.Department of Radiation OncologyIRCCS San Martino-IST National Cancer Research Institute and UniversityGenoaItaly
  9. 9.University of BresciaBresciaItaly

Personalised recommendations